Acute polyradiculoneuritis (AP) or Guillain-Barre Syndrome is usually a monophasic disease from which recovery is the rule. Nevertheless, the prognosis is variable and in the early stages unpredictable. Nearly a quarter of patients require artificial ventilation during the acute stage when, even in modern series, 5% die of respiratory complications, pulmonary embolism or cardiac arrythmia or circulatory collapse due to the autonomic neuropathy. About 10% of patients are left with significant disability due to persistent weakness of the limbs, and about 5% relapse. The variable prognosis suggests that even when the diagnostic criteria are rigidly defined (Asbury 1981) the syndrome includes more than one disease process.
Histologically human AP resembles experimental allergic neuritis. This is induced in laboratory animals by immunisation with peripheral nerve myelin in complete adjuvant. The best model is the inbred Lewis rat in which injection of bovine intradural nerve root myelin causes limpness of the tail after about 11 days and then a progressive tetraparesis. After one or two weeks the rats begin a recovery which is eventually complete. The antigen responsible for experimental allergic neuritis has been identified as a basic protein called P2, molecular weight 15,000, which is present in peripheral nerve myelin in much greater amounts than in central nervous system myelin. The major immune mechanism responsible for the experimental disease is probably T-cell mediated (Hughes et al 1981) . Antibodies to P2 cannot be detected in human AP and the issue of cell-mediated immunity to P2 has not been decided (Iqbal et al 1981) . Neverthless, the favourite hypothesis remains that human AP is due to a virus induced cell-mediated autoimmune reaction directed against myelin.
In experimental allergic neuritis the serum does contain antibodies which react with myelin. Anti-myelin serum will cause demyelination of myelinated nervous tissue cultures in vitro. Furthermore, in vivo injections of small amounts of such serum into rat sciatic nerve cause marked myelin dissolution several hours before cells are visible in the lesion. These effects can be abolished by absorption of the serum with galactocerebroside and reproduced with anti-galactocerebroside serum (Saida et al 1981) . Galactocerebroside is an important glycolipid con-stituent of myelin. Antibodies to galactocerebroside have been sought in the serum of patients with AP but not found. Antibodies reacting with nerve extract and mylino toxic antibodies have been reported in the serum of patients with AP (Cook and Dowling 1981) but they are difficult to detect and doubts remain about their importance. The pathogenesis of AP is a field of active research but remains unknown and does not provide a clear theoretical basis for immunosuppressive treatment.
The hints of circulating myelinotoxic factors in patients with AP have been sufficient to stimulate several attempts at treatment with plasma exchange. De Jager et al report rapid improvement in one patient who had had symptoms for 29 days and had been ventilated for 18 days in the plateau phase of the disease. In another patient progression stopped soon after plasma exchange was started on the sixteenth day of the illness. In three other patients no definite effect was observed including one patient in whom treatment was started on the ninth day. These patients as a group seemed to improve slightly faster than a historical control group from the same institution. This series is representative of most other anecdotal reports in literature (Asbury et al 1980) and helps by including unsuccessful cases like the two reported by Maisey and Olczak (1981) as well as the successful cases which tend to be over-reported. Rumpl et al (1981) have reported the most dramatic series in which plasma exchange was reported beneficial in all of eight acute cases: the most obvious benefit was observed in patients who were still worsening during the first two weeks of their illness. Dureux et al (1980) also report apparent benefit from plasma exchange in all of four cases of AP treated within a week of onset. Nevertheless in some reported cases, like case 4 of de Jager et al early treatment has been unsuccessful. No method of predicting benefits from plasma exchange has been identified and the apparent responses to this treatment may have been due to spontaneous recovery.
Similar arguments raged about the use of steroids for nearly 30 years before a controlled trial failed to support the use of prednisolone (Hughes et al 1978) . Evaluation of the role of plasma exchange will have to await the outcome of similar controlled trials: separate multicentre investigations are in progress in the United Kingdom and the U.S.A.
Chronic relapsing polyradiculoneuritis usually has a slower onset than AP and subsequently pursues a relapsing course. The clinical manifestations, neurophysiological findings and histology closely resemble AP. Chronic relapsing polyradiculoneuritis, unlike AP, is associated with HLA-B8, -DRW3, and HLA type often associated with autoimmune disease. Unlike AP it usually responds to steroids (Dal akas and Engel 1981). Some patients with chronic relapsing polyradiculoneuritis have seemed to benefit from plasma exchange (Server et al 1979 , Levy et al 1979 . There is no guarantee that the chranic relapsing form of polyradiculoneuritis has exactly the same immunological mechanism as AP and these results should not be extrapolated to the treatment of the acute monophasic form of the disease. Finally, even if plasma exchange were beneficial in AP, that benefit would not necessarily be due to the removal of antibody. The blood is effectively being washed and the removal of Iymphokines, antigen antibody complexes and other factors may be important.
